Drugs / NM1F
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05746897 | Apr 2023 → Sep 2027 expected | colorectal cancer, melanoma, ovarian cancer, triple-negative breast carcinoma | Hefei TG ImmunoPharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NM1F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05746897 ↗ |
| Action | Inhibit | “NM1F(Anti-PVRIG)” NCT05746897 ↗ |
| Target | PVRIG | “NM1F(Anti-PVRIG)” NCT05746897 ↗ |